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Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways
have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST)
pathways have emerged as some of the major pathways implicated in the development of HCC. Physiologically,
GH-IGF-SST system plays a crucial role in liver growth and development since GH induces IGF1 and IGF2 secretion
and the expression of their receptors, involved in hepatocytes cell proliferation, differentiation and metabolism. On
the other hand, somatostatin receptors (SSTRs) are exclusively present on the biliary tract. Importantly, the GH-IGF-
SST system components have been indicated as regulators of hepatocarcinogenesis. Reduction of GH binding
affinity to GH receptor, decreased serum IGF1 and increased serum IGF2 production, overexpression of IGF1 receptor,
loss of function of IGF2 receptor and appearance of SSTRs are frequently observed in human HCC. In particular, recently,
many studies have evaluated the correlation between increased levels of IGF1 receptors and liver diseases and the
oncogenic role of IGF2 and its involvement in angiogenesis, migration and, consequently, in tumour progression. SST
directly or indirectly influences tumour growth and development through the inhibition of cell proliferation and
secretion and induction of apoptosis, even though SST role in hepatocarcinogenesis is still opened to argument.
This review addresses the present evidences suggesting a role of the GH-IGF-SST system in the development and
progression of HCC, and describes the therapeutic perspectives, based on the targeting of GH-IGF-SST system, which
have been hypothesised and experimented in HCC.
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Hepatocellular carcinoma (HCC) represents the sixth
most common cancer and the third leading cause of
mortality for malignancy in the world [1]. HCC is the pre-
dominant type of hepatic carcinoma, accounting for 90%
of liver primary malignant tumours [1-3]. The Barcelona
Clınic Liver Cancer (BCLC) staging system is re-
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reproduction in any medium, provided the orprediction and treatment allocation of HCC [1,4,5].
BCLC staging classification is based on variables re-
lated to tumour stage (number and diameter of tumour
nodules and presence of portal invasion and metasta-
sis), liver function (Child-Pugh class) and general
health status (performance status test), that define five
groups of patients with HCC (0, A, B, C and D) and
link these groups to a specific treatment strategy and a
different prognosis [1,4,5]. In particular, according to
BCLC staging system, the “stage 0” includes patients
with very early HCC; the “stage A” patients with early
HCC; the “stage B” patients with intermediate HCC; the
“stage C” patients with advanced HCC and the “stage D”
patients with endstage disease [1,4,5].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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from normal liver, through chronic hepatitis and/or cir-
rhosis and formation of dysplastic nodules, to HCC.
Indeed, HCC rarely arises in non-cirrhotic liver (about
20%), while it often develops on pre-existing cirrhosis
(about 80%), primarily due to hepatitis B virus (HBV)
or C virus (HCV) infection or alcohol consumption.
The aetiological factors (virus infection, alcohol con-
sumption, genetic disorders of metabolism, hereditary
hemochromatosis, tobacco smoking, aflatoxins, drugs
and radiations) may vary depending on ethnic group or
geographic area of the patients affected by this malig-
nancy [1,6]. These evidences suggest that several patho-
logical agents, able to induce liver damage, can stimulate
an inflammatory and hyperproliferative response in he-
patocytes by activating and/or inhibiting several cell mo-
lecular pathways. Liver damage, chronic inflammation
and the hyperproliferative hepatocytes status predispose
to the accumulation of genetic and epigenetic alterations
that determine the development of HCC [6-15]. The
types and the sequence of the occurrence of genetic and
molecular alterations associated with hepatocarcinogen-
esis have not been fully clarified and they seem to be
highly tumour-specific [16]. The commonly altered path-
ways in HCC include: IGF (in particular IGF2 and down-
stream mediators, as mTOR), p16/pRb (DNA repair
pathway), p53/p21 (cell-cycle pathway), β-catenin, and
trasforming growth factor (TGF) [6-18]. A schematic
model of hepatocarcinogenesis is presented in Figure 1.
The GH-IGF-SST system is an endocrine system con-
sisting of growth hormone (GH), insulin-like growth fac-
tors (IGF1 and IGF2) and the relative associated carrier
proteins and receptors, and somatostatin (SST), control-
ling human prenatal development and postnatal growth
by regulating cell proliferation, differentiation and me-
tabolism [19]. The liver occupies a central role in this
endocrine system, because it produces many of its com-
ponents and it is also a target of their actions [20].
Therefore, liver injury affects the function of GH-IGF-
SST system and, in turn, the alteration of GH-IGF-SST
system may play a role in the development of liver dis-
eases, such as cirrhosis, fibrosis and HCC [21].
The GH-IGF-SST system seems to play a role in the
development of various malignancies, including HCC.
Indeed, in several types of cancer, GH-IGF1 axis has
been demonstrated to affect tumour cell proliferation,
apoptosis and invasiveness, and tumour angiogenesis
[22,23]. Changes in the expression pattern of GH-IGF
axis have been reported in HCC, suggesting that this
system plays a role in hepatocarcinogenesis [24].
Additionally, the activation of somatostatin receptors
(SSTRs) may elicitate antitumoural effects through both
direct (inhibition of cell proliferation and induction of
apoptosis) and indirect (inhibition of cell proliferationand angiogenesis through the suppression of growth fac-
tors and growth-promoting hormones, such as GH and
IGF1) mechanisms [25,26]. HCC has been reported to
express SSTRs, although literature data about the anti-
neoplastic effects of the somatostatin analogues (SA) in
HCC are still controversial [27,28].
The aim of this review is to analyse the role of GH-
IGF-SST system in the development of HCC, mainly fo-
cusing on the underlying biological and molecular
mechanisms and on the possibility to target this pathway
as a new treatment strategy in HCC patients.
GH-IGF-SST system: an outline
The GH-IGF-SST system is composed by three essential
components: ligands (GH, IGF1 and IGF2, SST), re-
ceptors [GH receptor (GHR), IGF1 receptor (IGF1R),
IGF2 receptor (IGF2R) and SSTRs)] and binding pro-
teins [GH binding protein (GHBP) and IGF binding
proteins (IGFBPs)].
GH is mainly produced and secreted in a pulsatile
manner by the anterior pituitary gland and represents
the main regulator of postnatal growth, by controlling
cell secretion, metabolism, survival and proliferation
[29,30]. GH promotes IGF1 gene transcription and syn-
thesis in the liver, thus regulating the circulating levels
of IGF1 [31].
GH secretion is strictly controlled by the hypothalamic
neuropeptides growth hormone releasing hormone
(GHRH) and SST. GHRH is produced in the arcuate nu-
cleus of the hypothalamus and it represents the central
stimulator and regulator of GH synthesis and release.
SST is produced in the periventricular nucleus of the
hypothalamus and it mediates the negative feedback op-
erated by GH on its own release, by acting through
seven transmembrane domain G-protein-coupled recep-
tors, the SSTRs subtypes 1–5 [32]. SSTR2 has been re-
ported to be the dominant SSTR influencing GH release
from the somatotroph cells; the inhibition of Ca2+ influx
(through L- and T-type voltage-sensitive channels), the
stimulation of K+ influx and the inhibition of cAMP
levels have been reported to be the dominant signal
transduction involved in this SSTR2 function [33]. GH
action is mediated via GHR, which is widely expressed
in many human tissues. GHR exists as pre-formed di-
mers; conformational changes induced by ligand binding
activate signal transduction [34]. GH/GHR dimer inter-
action mainly results in the activation of different tyro-
sine kinases. The activation of JAK2, a protein of Janus
kinase family, is thought to be the key regulator of GH
transduction signalling. Several signalling proteins and
downstream pathways are activated as a consequence of
GHR/JAK2 complex formation, including STAT (signal
transducers and activators of transcription) 1, 2, 3 and 5
(mainly 5a and 5b), phosphatidylinositol 3-kinases
Figure 1 Scheme of hepatocarcinogenesis and relation with GH-IGF-SST system. Hepatocarcinogenesis is a multistep process generally
evolving from normal liver through chronic hepatitis, cirrhosis and formation of dysplastic nodules to HCC. Several hepatocarcinogens (virus
infection, alcohol consumption, genetic disorders of metabolism, hereditary hemochromatosis, tobacco smoking, aflatoxins, drugs and radiations)
could cause direct or indirect damage to hepatocytes DNA (genetic change?), thus inducing a hyperproliferative status and inflammatory
reactions, in particular during chronic exposure. The persistent liver damage can lead to the activation and/or inhibition of several molecular cell
pathways, predisposing to the accumulation of genetic and epigenetic alterations that determines HCC development. The most important
changes of molecular pathways described in HCC are reported in the text box on top of the figure. The most important changes in GH-IGF-SST
system occurring during the different steps of HCC development are reported in the text boxes on the bottom of the figure.
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[34]. STAT5a and STAT5b activation is critical for some
important GH functions, including the regulation of body
growth and metabolism, and, in particular, the stimulation
of IGF1 synthesis [35] and the regulation of the expression
of crucial liver genes [30,36]. Figure 2 shows a simplified
scheme of the GH-activated intracellular pathways.
GHBPs are produced by a proteolytic cleavage of GHR at
the site proximal to the cell surface. GHBPs bind about
half of the circulating GH and have several and complex
functions, including the modulation of plasma GH half-
life and the binding of GH to GHR [37].
IGF1 plays an essential role in the body growth and
metabolism, especially during the postnatal life, through
the activation of IGF1R. It has been suggested that
serum IGF1 postnatally supplied by the liver plays an
endocrine role that is nearly as significant for the growth
as the autocrine/paracrine action of IGF1 produced lo-
cally in various tissues [33]. On the other side, serum
IGF1 exerts a negative feedback on GH production, by
directly inhibiting the pituitary gland secretion and in-
directly stimulating SST and inhibiting GHRH secretion
[33]. IGF2 is a circulating peptide hormone whose regu-
lation can be under the control of GH [38]. IGF2 playsan important role in the body growth and metabolism,
especially during the prenatal life. Indeed, IGF2 is prefer-
entially expressed during embryogenesis and foetal de-
velopment, it stimulates cell growth and proliferation
and it promotes embryo and fetus growth, by activating
IGF1R and insulin receptor (IR), in particular the iso-
form A (IRA), which is predominantly expressed during
prenatal life [39,40]. IGF2 can also bind to IGF2R, which
is considered a “scavenger receptor”. Indeed, the binding
of IGF2 to this receptor assigns IGF2 to degradation to-
wards the lysosomes and does not elicit any proliferation
or survival signals [41,42]. Overall, IGFs may also play
an autocrine or paracrine role by binding to IGF1R and/
or IR on target cells [43,44]. IGFs are involved in many
cell processes, including cell differentiation, cell growth
and proliferation, and apoptosis. These effects are pre-
dominantly mediated by the activation of two signalling
cascades: MAPK and PI3K pathways. The binding of
IGFs to their receptor tyrosine kinases (RTKs) triggers
the phosphorylation of several substrates, including insu-
lin receptor substrate (IRS1-4) proteins, leading to the
activation of PI3K and, subsequentially, to the activation
of the serine-threonine kinase (AKT) and downstream
signalling effectors, including the mammalian target of
Figure 2 Intracellular pathway associated with GHR activation in hepatocytes. GH exerts its effect by binding to the extracellular domain of
the GHR, where one molecule of GH binds two GHRs increasing the affinity of both receptors for two molecules of JAK2, which phosphorylate
the GHR. GHR activation, in turn, triggers the activation of several signal transduction pathways, including STAT and PI3K through IRS. IRS and
PI3K can activate nuclear transcription factors, including c-FOS and c-JUN, to induce cell proliferation and differentiation but also can increase
glucose transport. GH-induced JAK2 activation phosphorilates STAT5 which translocates into the nucleus where binds to response elements in
the regulatory regions of target genes including IGF1 and EGFR. The activation of adaptor protein SHC leads to the activation of MAPK involved
in cell proliferation and growth.
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p70 ribosomal protein S6 kinase (RPS6KB1). In addition,
IRS1 and IRS2 can activate rat sarcoma viral oncogene
homolog (RAS) and, subsequentially, the MAPK pathway,
including mitogen/extracellular signal-regulated kinase
(MEK) and extracellular signal-regulated kinase (ERK)
[44]. Figure 3 shows a simplified scheme of the IGF-
activated intracellular pathways.
The IGFBP superfamily includes six proteins (IGFBP1-
6), which are able to bind the IGFs with different affinity.
IGFBP-IGF complexes influence IGFs activities by
modulating their half-life and tissues bioavailability [45].
IGFBPs are produced by a variety of different tissues:
IGFBP1 expression is restricted to the liver, IGFBP2 ex-
pression is predominat in tissues derived from ectoderm
and endoderm, IGFBP3 and IGFBP4 are expressed in a
specific subset of mesenchymal cells and IGFBP5 is
expressed in tissues derived from ectoderm and muscle
precursor cells [45]. IGFBPs are considered pleiotropic
molecules, with IGF-dependent and IGF-independent
actions. About 80% of circulating IGF1 is bound to
IGFBPs, mainly to IGFBP3. IGFBP3 is the most abun-
dant binding protein and binds IGF1 or IGF2 and the
acid-labile subunit (ALS) protein, forming a ternary
complex [43,44]. ALS is a glycoprotein that interacts
with IGFBP3 only when IGFBP3 is associated to IGF1 or
IGF2 [43,44]. This phenomenon is possible because, in
normal conditions, the total IGFs and IGFBP3 arepresent in the serum at equimolar concentrations. To a
smaller degree, IGFBP5 also forms a ternary complex
with IGFs and ALS [45,46]. ALS increases the molecular
mass of the IGF/IGFBP3 complex, by modulating the
amount of IGFs that can diffuse to the extracellular
fluids [45]. The other IGFBPs with low molecular mass
do not form a ternary complex with any other protein,
and mainly circulate associated in a binary complex with
IGF1 or IGF2 [45,46]. IGF-independent actions of IGFBPs
include effects on cell proliferation, apoptosis, motility
and migration and they can be mediated by either intact
IGFBPs or by their proteolysed fragments [47,48]. A sche-
matic outline of GH-IGF-SST system in human adult life
is represented in Figure 4.
The GH-IGF-SST system: a focus on liver
The liver is the major target organ of GH, since GH in-
duces IGF1 expression and secretion in hepatocytes, the
liver parenchymal cells and, at a lesser extent, in cholan-
giocytes [49]. Moreover, in hepatocytes, GH is also de-
puted to the regulation of glucose metabolism by
reducing glucose uptake and promoting gluconeogenesis
[50].
IGF1 and IGF2 have broad insulin-like actions, includ-
ing promotion of energy storage and fatty acid synthesis
in the liver. In mice and humans, the circulating IGF1
derives predominantly from hepatocytes [51,52]. The
IGF1 derived from the liver has a central role as
Figure 3 Intracellular pathway associated with IGF1R activation. IGF1R activation by INS, IGF1 and IGF2, leads to autophosphorylation on
tyrosines 1131, 1135 and 1136 in the kinase domain, followed by recruitment of specific docking intermediates, such as members of the IRS
family (IRS-1, IRS-2, IRS-3, IRS-4). This molecule link the IGF1R to diverse signalling pathways, allowing the induction of growth, transformation,
differentiation and protection against apoptosis, primarily through the activation of the PI3K/Akt/mTOR and the Ras GTPase/Raf-1 (Raf)/Mek
(MAPK)/Erk (ERK1/2) signalling pathways.
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Indeed, studies conducted in bitransgenic mice with
IGF1 gene expression in the liver but not in extrahepatic
tissues, have demonstrated that the growth rate of these
mutated mice was not significantly different from wild-
type animals, suggesting that IGF1 derived from the liverFigure 4 Outline of endocrine, autocrine and paracrine GH-IGF-SST sy
IGF1 is mainly produced in the liver and IGF1 levels are under the control o
delivered by circulation but it can also be produced in an autocrine or paris important but not essential for the postnatal growth
[53]. IGF1 produced in extrahepatic tissues also plays an
important role as autocrine and/or paracrine regulator
of postnatal growth. Indeed, studies conducted in knock-
out mice, with liver-specific deletion of IGF1 gene and
normal IGF1 gene in extrahepatic tissues, demonstratedstem in human adult life. At the whole organism level, circulating
f GH. In turn, GH is regulated by SST and GHRH. IGF1 is usually
acrine manner.
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nificantly different from wild-type animals, thus the
IGF1 produced in extrahepatic tissues is important but
not essential for the postnatal growth [54,55]. Therefore,
both IGF1 produced in the liver and IGF1 produced in
extrahepatic tissues play an important role in the post-
natal growth, in both an endocrine and autocrine/para-
crine manner [53-55].
IGF2 expression has been demonstrated in rat hepato-
cytes, Kupffer cells (KCs), hepatic endothelial cells (ECs)
and hepatic stellate cells (HSCs) [56,57], and in human
foetal and adult hepatocytes [52,58]. IGF2 gene tran-
scription largely varies during development, depending
on the activation of distinct patterns of four different
IGF2 gene promoters (P1-P4). In rodents, promoters P2,
P3 and P4 are active during foetal growth in the liver,
whereas, after birth, P1 becomes the dominant promoter
and P2-P4 decrease their activity [59]. In humans, the
transcription of IGF2 during foetal development is pref-
erentially under the regulation of P2, P3, P4 promoters,
while all promoters regulate IGF2 transcription from
two months after birth onwards [58].
IGF1R has been reported to be abudantly expressed in
rat KCs, ECs and HSCs, whereas its expression in rat he-
patocytes is scant, suggesting that IGF1 does not have a
strong autocrine/paracrine direct effect on hepatocytes
in this animal model [57,60]. IGF2R is expressed in rat
non-parenchimal liver cells [57]. No studies reported
IGF1R and IGF2R expression in human normal liver.
IGFBP1, IGFBP2, IGFBP4 and ALS are produced by rat
hepatocytes [61-63], whereas IGFBP3 seems to be pro-
duced by rat KCs, ECs and HSC [64,65]. In humans,
messenger and protein expression of IGFBPs has been
evaluated in the liver. IGFBP1, IGFBP2 and IGFBP4
messenger and protein are widely expressed in the par-
enchymal cell population; IGFBP3 messenger and pro-
tein are localized in KCs [52,66]; IGFBP5 is produced by
HSCs [67]. These binding proteins, involved in the con-
trol of the pool of bioactive IGFs, are under the control
of the nutritional status and well correlate with the liver
functional reserve [68]. Several studies demonstrated
that insulin, glucagon and IGFs are able to regulate the
transcription of IGFBPs genes [65,68,69].
No studies reported SSTRs expression in mouse or rat
normal liver. SSTRs expression has been evaluated in a
human normal hepatocytes cell line, the L-02, in which
SSTR2 and SSTR4 messengers have been detected by
molecular techniques [70]. However, SSTRs protein ex-
pression has been reported in human normal liver tissue,
at the level of cholangiocytes, but not in hepatocytes
[27,71]. The main action of SST in the liver has been ex-
plored in pre-clinical in vivo studies. In rats subjected to
bile duct ligation, SST affects cholangiocytes choleretic
activity, by counteracting the effect of secretin on thebiliary excretion of water and bicarbonate by cholangio-
cytes, in cholestatic conditions [72]. Moreover, studies
performed in rats have demostrated that SST has a role
in the regulation of lipid metabolism [73].
The GH-IGF-SST system in hepatocarcinogenesis
A large number of studies has evaluated the role of GH-
IGF-SST system in the development and progression of
HCC, but results are controversial (Figure 1).
GH and GH receptor
The role of GH on the development and progression of
HCC is still matter of controversies.
In a preclinical setting, the use of recombinant human
growth hormone (rhGH) has been tested predominantly
in in vitro studies conducted in two HCC cell lines: Bel-
7402 and SMMC-7721 [74]. Among these cell lines, only
Bel-7402 cells were found to express GHR messenger
[74]. The treatment with rhGH induced an increase of
the percentage of cells in mitotic phase G2-M, as well as
an increase of cell invasion and proliferation in Bel-
7402, but not in SMMC-772 [74]. In addition, rhGH
treatment induced an overexpression of vascular endo-
thelial growth factor (VEGF) in Bel-7402 cells, but not
in SMMC-7721 [74]. Based on this preclinical study, it
can be speculated that rhGH could affect HCC growth
in GHR positive HCC, both directly and indirectly, via
VEGF secretion. The binding of GH to GHR triggers the
activation of intracellular signals, among which the pre-
dominant effector is Stat5 [30]. Although the activation
of Stat5 has been associated with tumourigenesis of se-
veral solid tumours [75], in the liver, Stat5 has a role as
tumour promoter but it seem to have also a potential
role as tumour suppressor gene [75,76]; therefore, the
role of Stat5 in hepatocarcinogenesis is still debated.
Stat5b enhances HCC cell aggressiveness through the in-
duction of epithelial-mesenchymal transition, as demon-
strated in a human transfected HCC cell line [77]. In
apparent contrast, loss of STAT5 in mice caused liver
steatosis and fibrosis, and promoted chemically induced
HCC, by up-regulating the TGF-beta (TGF-β) and by al-
tering the expression of cell cycle pathway regulators
[76,78]. Liver steatosis results from excessive synthesis of
free fatty acid, whose release is regulated not only by
GH bu also by glucocorticoids (GCs). Recently, in a
study investigating the role of combined deletion of he-
patic STAT5 and glucocorticoid receptor (GR) in mice,
it has been observed that the block of GH and GCs sig-
nallings induces lipid accumulation in the liver, which,
in turn, contributes to liver chronic inflammation with
progression to cirrhosis; this condition subsequently
promotes tumorigenic transformation of hepatocytes
[79]. This study suggests that hepatic GH signalling is cru-
cial for the maintenance of lipid homeostasis and that the
Pivonello et al. Infectious Agents and Cancer 2014, 9:27 Page 7 of 23
http://www.infectagentscancer.com/content/9/1/27impairment of this signalling causes severe metabolic liver
disease predisposing to HCC.
Few studies reporting GHR expression in HCC are
presently available in literature [80-82]. In one of these
studies, GHR expression has been investigated in 40 dif-
ferent samples of HCC tissues: GHR was undetectable in
5 samples, whereas in the remaining 35 HCC tissues
GHR was expressed but it was associated with a lower
GH binding ability compared to normal liver [82], sug-
gesting that HCC could be partially resistent to GH
stimulation. In HCC patients undergoing hepatectomy,
rhGH has been evaluated as a potential treatment to
improve the protein catabolism that complicates major
surgical procedures. In this study, 24 HCC patients were
randomly assigned to two postoperative treatment
groups: parental nutrition vs parental nutrition plus
rhGH. In the last group an increase of GH-IGF1 axis
(evaluated as circulating IGF1 and IGFBP3) was ob-
served without any change in tumour-free survival rates
and median tumour-free survival time [83]. Chronic liver
diseases were found to be associated with increased cir-
culating GH levels, compared with healthy subjects
[84,85]. However, in patients with cirrhosis, despite the
increase in circulating GH levels, serum IGF1, IGFBP3
and ALS levels and the IGF1 response to GH were
found to be lower than in controls, resembling a condi-
tion of GH resistance, as a consequence of liver dysfunc-
tion [86].
In summary, in vitro data suggest that GH can stimu-
late human HCC cell proliferation but patients with
HCC seem to have a condition of GH resistence that
might reduce these effects in an in vivo setting Further
studies are still necessary to better address the role of
GH in hepatocarcinogenesis.
IGF1 and IGF2
The role of IGF1 and IGF2 on the development and pro-
gression of HCC has been widely studied.
IGF1 and IGF2 messenger expression in human HCC
cell lines is reported in literature with conflicting results.
Personal unpublished data seem to suggest that HepG2
and HuH-7 cell lines do not express IGF1 but largely ex-
press IGF2 [87]. The high expression of IGF2 messenger
has been also reported in different studies [88,89], while
endogenous IGF1 messenger expression has been reported
in HepG2 and HuH-7 cell lines only in one study [90].
The role of IGF1 in hepatocarcinogenesis has been ex-
plored in preclinical settings, focusing on the ability of
IGF1 to regulate HCV infection. HCV RNA-containing
viruses are present in blood as hybrid particles, termed
lipoviroparticles (LVPs), composed by host lipoproteins
(low-density lipoprotein [LDL] and very-low-density
lipoprotein [VLDL]) and immunoglobulins. As part of
these LVPs, HCV are highly able to infect host cells bybinding lipoprotein receptors and escaping antibodies
recognition [91]. Recently, it has been demonstrated
that the lipolytic enzyme lipoprotein lipase (LPL) in-
hibits HCV infection by blocking virus cell entry in a
HCC cell line [92]. In a human HCC cell line it has
been reported that IGF1 downregulates LPL messenger
expression and reduces its enzymatic activity [93].
Therefore, IGF1 could play a role in hepatocarcinoge-
nesis by favouring HCV infection. In HuH-7 and
HepG2 cell lines, it has been showed that IGF2 down-
regulation decreases cell proliferation [94]. Addition-
ally, it has been reported that IGF2 gene is a “carrier”
for miR-483, an intronic micro-RNA (miRNA), which
is able to stimulate cell proliferation in HCC, through
the downregulation of its target Socs3 (suppressor of
cytokine signaling 3) [95]. IGF2 has also a role in
tumour cells migration and angiogenesis. Indeed, in
the human HCC cell line HepG2, under conditions of
hypoxia, IGF2 messenger expression has been found to
be increased, and, in turn, IGF2 has been shown to
stimulate VEGF cell production. Moreover, in HepG2,
the silencing of IGF2 gene has been shown to reduce
the secretion of VEGF in cell supernatants and to de-
crease the in vitro colony formation [96]. In in vivo
preclinical studies, it has been reported that IGF1 mes-
senger levels are lower in the liver tumour tissue than
in the tumour-surrounding tissue or healthy liver tis-
sue of mice harbouring HCC [97]. IGF2 messenger
levels are elevated in murine HCCs with enhanced
metastatic potential, as compared to murine low inva-
sive HCCs [98]. Dysregulation of IGFs could have a
role in the pathogenesis of at least a subset of HCCs.
The role of IGF1 is controversial. Several studies have
demonstrated that high serum IGF1 and low serum
IGFBP3 are associated with an increased risk of pros-
tate, breast, colorectal and lung cancer, and HCC
[99-101], probably due to the high bioavailability of
mitogenic IGF1. HCC associated with cirrhosis, re-
gardless of HBV and HCV infection, is characterized
by significantly lower levels of serum IGF1 than
healthy subjects [102,103]. In patients with liver cir-
rhosis, a condition of IGF1 deficiency is thought to re-
sult from the reduced synthetic capability of damaged
hepatocytes, as supported by the correlation between
IGF1 levels and albumin in cirrhotic patients [104]. In
HCC, the reduced binding of GH to the GHR could
contribute to the IGF1 deficiency [82]. Additionally, the
low circulating levels of IGF1 significantly correlate with
advanced clinicopathologic parameters and poor overall
survival in patients with HCC [105]. In a study evaluating
IGF1 and IGFBP3 levels in 40 cirrhotic patients, 63 HCC
patients and 150 healthy subjects, both serum IGF1 and
IGFBP3 levels were significantly lower in cirrhotic and
HCC patients than in controls. Interestingly, the IGF1/
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than in both cirrhotic patients and controls, suggesting
that HCC could be associated with an increased IGF1
bioavailability [101]. Therefore, it has been suggested that
IGF1/IGFBP3 ratio, more than IGF1 itself, could play a
role in hepatocarcinogenesis. Therefore, IGF1 bioactivity
could be an attractive parameter [100,106] to be investi-
gated in patients with chronic liver disease and HCC.
Conversely to IGF1, serum IGF2 levels in patients with
HCC were significantly higher than in patients with cir-
rhosis and healthy subjects [107-109].
Regarding the expression of IGFs in human liver tissues,
it has been reported that IGF1 messenger expression is
lower in HCC than in normal liver, while no relevant dif-
ferences have been found in liver tissues from patients
with chronic hepatitis, as compared with normal liver
[110,111]. However, IGF1 messenger expression is lower
in human chirrotic tissues than in both tumour and nor-
mal liver tissues [110,112]. IGF2 messenger has been re-
ported to be overexpressed in human liver with chronic
hepatitis, cirrhosis and HCC as compared with normal
adult liver [113-116]. Additionally, high IGF2 protein ex-
pression has been described in HBV- and HCV-positive
HCC tissues, compared with normal and HCC cirrhotic
and virus negative tissues [117,118]. The inactivation of
adult-specific IGF2 promoter (P1) [119] and the activation
of foetal-specific IGF2 promoters (P2-P4) could represent
the mechanism underlying IGF2 dysregulation in HCC
[120]. Indeed, in human HCC cell lines it has been shown
that HBV X protein stimulates P3 promoter activity and
HCV core protein is able to increase IGF2 P4 promoter
expression [121,122]. Therefore, HBV and HCV infection
can promote IGF2 overexpression, which is a common
feature of human HCCs. IGF2 transcription is also regu-
lated by aflatoxin B1, an HCC causative toxic compound
produced by Aspergillus molds, specifically through the
activation of P4 promoter. Indeed, aflatoxin B1 induces
a mutation in p53 gene, at the level of codon 249
(p53mt249), that strongly increases the activity of P4
[123]. Furthermore, in human HCC tissues it has been
demonstrated that VEGF and IGF2 gene-specific single
nucleotide polymorphisms are significantly correlated
to the expression of metastatic tumour antigen 1
(MTA1), a metastasis-associated protein involved in the
increase of cell migration and invasion [124].
In conclusion, IGFs seem to have a role in hepatocar-
cinogenesis. IGF1 has a main role in influencing HCV
infection capability, thus contributing to HCC develop-
ment. Moreover, the increased IGF1 bioavailability in pa-
tients with HCC, probably as a consequence of autocrine
secretion by the neoplasm, could be an important factor for
tumour progression. IGF2 is highly expressed in human
HCC, where it seems to have a stimulatory effect on
tumour cell proliferation. Additionally, IGF2 can beresponsible, at least partially, of HBV, HCV and afla-
toxin carcinogenic effects.
IGF receptors
The role of IGF receptors, expecially of IGF1R, on the
development and progression of HCC has been widely
studied.
The expression of IGF1R is significantly increased in
HCC in rats [65]. A growing body of evidences suggests
an increase in IGF1R expression in human cirrhotic
liver, hepatoma cell lines and HCC [64,88,125-128]. In a
preclinical setting, an up-regulation of IGF1R expression
has been identified in Hep3B, a human hepatoma cell
line transfected with p53mt249 [129], and in SNU368, a
human HCC cell line expressing HBV protein (HBx)
[130]. In physiological conditions, IGF1R protein is
downregulated by several miRNA [131]. miRNAs are a
new class of gene expression regulators that can control
cell proliferation and cancer. Particularly, several miR-
NAs, including miR-122, miR-21, miR-222 and miR-145,
seem to play a role in viral-induced liver damage, by
regulating hepatocyte infection and proliferation. Among
these miRNAs, miR-122 is a liver-specific miRNA abun-
dantly expressed in hepatocytes and known to modulate
lipid metabolism, HCV replication and apoptosis [132].
Persistent expression of miR-122 has been detected dur-
ing hepatic cell differentiation, while miR-122 is barely
detectable in primary human HCCs [132,133]. As dem-
onstrated in normal liver cells in physiological condi-
tions, miR-122 has been suggested to suppress IGF1R
expression, by binding to the untranslated region of the
messenger, which codifies for IGF1R, thus blocking
IGF1R translation. This block attenuates IGF1R/Akt sig-
nalling, resulting in an increased glycogen synthase
kinase-3 beta (GSK-3β) activity, that, in turn, suppresses
cyclin D1 expression and cell proliferation. On the other
hand, the activated GSK-3β maintains high levels of
miR-122 via CCAAT/enhancer binding protein alpha
(C/EBPα), which enforces IGF1R suppression [134]. In
pathological conditions, in particular in response to liver
insults by HCV infection, dysregulation of this circuit
may result in uncontrolled cell proliferation and, in turn,
in hepatocarcinogenesis, due to a reduction of miR-122
expression, phosphorylation of Thr222/226-C/EBPα, an
enhancement of IGF1R protein, and phosphorylation of
Ser9–GSK-3β [134]. Surprisingly, a preclinical study
showed that C/EBPα expression is also upregulated by
IGF2; this finding is unexpected considering that the
mitogen IGF2 should decrease the expression of tumour
suppressor genes such as C/EBPα [135]. Thus, IGF1R
play a role in a regulatory circuitry whose dysfunction
may contribute to the development of HCC.
In HCC, IGF1R expression seems not to be correlated
with tumour size, histological differentiation, capsular
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of IGF2R gene has been reported significantly reduced in
human HCC tissues, compared with surrounding normal
liver [137]. IGF2R loss of heterozygosity coupled with in-
tragenic loss-of-function mutations in the remaining allele
is a common event in hepatocarcinogenesis [138,139].
Mutations occurring in the IGF2 binding site of IGF2R
lead to increased bioavailability of circulating IGF2, thus
allowing IGF2 to activate IGF1R and IR, and to enhance
cell proliferation. This molecular event may favour HCC
progression [140]. Figure 3 shows the intracellular signal-
ling induced by IGF1R and IGF2R.
In conclusion, IGF1R is overexpressed in conditions
predisposing to HCC, such as cirrhosis, as well as in
HCC. IGF1R overexpression facilitates IGF2 oncogenic
activity. The reduction of miR-122 expression, poten-
tially induced by HCV infection, is an important regula-
tory mechanism of IGF1R overexpression, representing
a relevant link between IGF pathway and viral agents, in
particular HCV, and potentially between IGF pathway
and development of HCV-induced HCC.
GHBP
A decrease of circulating GHBP levels has been de-
scribed in patients with cirrhosis [141,142]. An in-
crease in GHBP levels have been reported in patients
with non-alcoholic fatty liver disease (NAFLD), as
compared to healthy subjects [143]. Moreover, it has
been clearly demonstrated that the most severe cirrho-
sis have significantly decreased circulating GHBP
levels [141]. A hypothesis for the increased GHBP
levels in NAFLD and the reduced GHBP levels in dif-
ferent chronic liver diseases, including cirrhosis, might
be that the two isoforms of the GHR have a different
pattern of expression in different liver diseases. In fact,
it has been demonstrated that a truncated form of the
GHR is normally expressed at low levels compared
with the full-length receptor, but shows a higher ability
to generate GHBP [144-146]. Some authors demon-
strated that in cirrhotic liver, the expression of the
truncated form of GHR was reduced compared with
the full-length isoform, and this may contribute to the
lower GHBP levels found in patients wirh cirrhosis
[147]. Conversely, in NAFLD, some authors have
hypothesised a higher expression of the truncated form
of the GHR and a higher GHBP production [143]. An-
other hypothesis for the increased GHBP levels in
NAFLD may be a higher production rate of GHBP
from adipose tissue; indeed, the abdominal fat, which
is increased in patients with NAFLD, is correlated with
GHBP levels [148].
To our knowledge, neither in vitro nor in vivo studies in-
vestigating the role of the GHBP in hepatocarcinogenesis
have been conducted up to date.IGFBPs
IGFBPs have high affinities for IGFs, thereby the activ-
ities of either IGF1 or IGF2 are modulated by their asso-
ciation with IGFBPs. This evidence suggests that IGFBPs
exert a protective effect towards the IGF-induced cell
proliferation, through the restriction of the availability of
these ligands for binding to IGF1R. IGFBPs regulate pro-
liferation, differentiation and apoptosis of various cell
types in an IGF-dependent and -independent manner
[48,149]. IGFBP3 is the most commonly investigated
binding protein. In preclinical setting, IGFBP3 has been
demonstrated to induce a significant reduction of cell
proliferation and invasion, in several human HCC cell
lines (HAK-1B, KIM-1, KYN-2 and HepG2), through the
reduction of the bioavailability of endogenous IGF2 for
cell surface receptor binding [150,151]. Moreover, IGFBP3
attenuates also the proliferative action of IGF1. Indeed, in
HepG2 cell line, it has been demonstrated that, in the
presence and absence of IGF1, IGFBP3 attenuated the
IGF1-induced proliferation at low concentrations and
completely abolished the IGF1-induced proliferation at
high concentrations. These results suggest that, at least in
HepG2, IGFBP3 attenuates IGF1-induced proliferation by
binding IGF1 and, therefore, reducing IGF1 bioavailability
to its receptor [151]. Immunohistochemical analysis of
HCC tissues, which express IGFBP3, reveals abnormalities
in TGF-β and/or retinoblastoma protein (Rb) pathways.
These results opened the question whether IGFBP3 may
mediate growth suppression via the TGF-β and/or Rb
pathways in HCC; however, this issue needs to be further
investigated [152].
The expression of IGFBP1, 2, 3 and 4 in cirrhotic liver
is similar to normal liver tissues, but it is significantly
downregulated in HCC tissues, compared with normal
and cirrhotic liver [153]. In HCC patients, reduced ex-
pression of IGFBP3 has been found to be significantly
correlated with tumour size, histological differentiation,
capsular invasion, portal venous invasion and poor sur-
vival [150]. Promoter hypermethylation of IGFBP3 gene
has been suggested as a potential mechanism for
IGFBP3 downregulation in HCC [154]. IGFBP3 levels
were negatively correlated with liver function measured
as Child-Pugh class in patients with liver cirrhosis and,
weaklier, in those with HCC, as compared with healthy
subjects [101,107]. The estimation of serum IGF1, IGF2
and IGFBP3, together with Child-Pugh score, is more
effective in predicting liver dysfunction and its severity,
compared to Child-Pugh score alone [107].
In conclusion, IGFBP3 is downregulated in HCC and it
is correlated with important clinical parameters. There-
fore, IGFBP3 could play an indirect role in HCC develop-
ment by reducing IGF1 bioavailability to its receptor,
and could be a molecular target for novel therapeutic
strategies in HCC patients.
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An in vitro study provided the evidence that HepG2 cell
line does not produce SST but it does produce cortista-
tin (CST), a neuropeptide showing high structural hom-
ology with SST and binding to all SSTRs [155]. SSTRs
expression has been heterogeneously demonstrated by
in vitro studies in human HCC cell lines, including
HepG2, HepB3, HuH-7, SMMC-7721 and Bel7402, with
different findings among the various cell lines, as well as
in the same cell line investigated in different studies
[27,70,155-158]. However, SSTR2 expression has been
homogeneously documented in the entire series of cell
lines [27,70,155-158]. Immunocytochemistry analysis
showed that SSTRs were located mainly intracellularly
in HepG2 and HuH-7 cells [155,158]. It has been sug-
gested that endogenous production of CST may be re-
sponsible for SSTRs internalisation and modification in
these cell lines [155].
The expression of SSTR2 has been demonstrated in
tissues of mice in which HCC was induced by treatment
with diethylnitrosamine [159]. The expression of SSTRs
has been largely demonstrated in both resectable and
unresectable human HCC tissues [27,160-163]. SSTRs
protein expression has been reported to be unrelated to
tumour stage, differentiation, histological tumour type
and/or underlying liver disease [164]. However, a recent
study evaluating the expression of SSTR2 and SSTR5 in
76 tumour samples from patients with HBV-related op-
erable HCC, found that, in this particular subset of pa-
tients, the mean survival time was longer in the
subgroup of patients expressing high SSTR2 and SSTR5,
and that, at multivariate Cox analysis, tumour expression
levels of SSTR2 were an independent prognostic marker
[161]. Moreover, progressive upregulation of SSTRs dur-
ing the different stages of hepatocarcinogenesis has been
also documented [27]. In this study, SSTRs were not
expressed in hepatocytes from normal liver, whereas they
were expressed in cirrhotic liver and HCC, although
with variable intensity [27]. Somatostatin receptor scin-
tigraphy with 111indium pentetreotide (Octreoscan) has
been used to screen HCC patient for SSTR2 and/or
SSTR5 positivity. In two different cohort of patients in-
cluding 127 and 70 patients, SSTR2 positivity was regis-
tered in 48% and 35.7% of patients, respectively [165].
These data demonstrated that at least a subgroup of pa-
tients with HCC presents SSTR2 and/or SSTR5 expression.
In HCC, the positivity at Octreoscan was not related with
the main clinical parameters [165,166]. However, the role of
SSTR expression in HCC tissues and of Octreoscan positiv-
ity in patients with HCC should be better addressed.
In conclusion, SSTRs are expressed in HCC cell lines as
well as in cirrhotic tissues and HCC, but SSTRs express-
sion seems to be not correlated with tumour stage, grad-
ing and prognosis.Targeting GH-IGF-SST system in hepatocellular carcinoma
Several approaches to GH-IGF-SST system targeting
have been used as novel therapeutic strategies in HCC,
and some others are currently under evaluation
[167,168]. Generally, molecular therapeutic strategies in-
clude the use of antibodies, which can have anti-ligand
and/or anti-receptor activity, the use of small molecules
inhibitors, which can interfere with key enzymatic func-
tions, and the use of synthetic receptor agonists or an-
tagonists [25,169,170]. All these approaches can interfere
with cell proliferation and/or, specifically, with apoptosis.
Monoclonal antibodies and small molecule inhibitors
can be used to target receptors, particularly growth
factor-RTK. These growth factor-RTK targeting ap-
proaches can be combined with different small molecule
inhibitors targeting cytoplasmic oncogenic kinases [170].
Figure 5 shows the therapeutic strategy involving GH-
IGF-SST system in the treatment of HCC.
GH and GH receptor
The modified GH analogue pegvisomant was the first spe-
cific GHR antagonist to be genetically engineered and pro-
duced by the pegylation of mutant GH [171]. The
pegylation has the benefit to increase the half life of drugs
and sterically interfere with GHR dimerization at the cell
surface, which is essential for GHR activity [171]. The anti-
tumour activity of pegvisomant has been tested in breast
cancer, colorectal cancer and meningiomas [172-174]. In
in vivo studies on animals, pegvisomant caused tumour
shrinkage in nude mice xenografted with a human breast
cancer cell line (MCF-7) and with two different human
colorectal cancer cell lines (COLO 205 and HT-29); in
these models a decrease of cell proliferation and the in-
duction of apoptosis were clearly demonstrated [172,173].
Pegvisomant has been also demonstrated to significantly
reduce the growth of meningioma in athymic mice xeno-
grafted with human meningioma primary cultures [174].
To the best of our knowledge, no studies have evalu-
ated the effects of pegvisomant in preclinical or clinical
models of HCC, but the GHR expression and GH effect
on HCC permit to hypothesize a role of pegvisomant in
this tumour.
IGF pathway
IGF pathway has been a target for the treatment of vari-
ous tumours for long time. Two kinds of target therapy
are usually used in clinical setting: anti-ligand and anti-
receptor drugs treatment. A list of the currently available
agents targeting IGF pathway, evaluated in clinical trials
for the treatment of HCC, is shown in Table 1.
Anti-ligand approach
MEDI-573, a human IgG2 monoclonal antibody (mAb),
is one of the first monoclonal antibodies produced
Figure 5 Several strategies in the therapeutic considerations involving GH-IGF-SST system in the treatment of HCC. Dotted black arrows:
activation by endogenous ligand. Black arrow: activation by exogenous ligand. Red lines: blocking of ligands and receptors.
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IGF2 without cross-reactivity to insulin. However, since
it acts by neutralising IGFs, it blocks the IGF-induced
activation of both IGF1R and IR downstream signalling
pathways. This double effect has been confirmed by
in vivo experiments in athymic mice xenografted with
two mouse fibroblast cell lines: P12, engineered to over-
express human IGF1 and IGF1R proteins but not human
IGF2, and C32, engineered to overexpress IGF2 and
IGF1R proteins but not IGF1 [175]. Moreover, in thisTable 1 Currently available agents against the IGF pathway e
Compound Company Mechanism of action Phase of clinica
development


















AVE-1640 Sanofi-Aventis Humanized mAb
anti- IGF1R
1/2
OSI-906 AstellasPharmaInc Small molecule
inhibitor of IGF1R
2
Data from clinicaltrials.gov.study, it has been demonstrated that MEDI-573 signifi-
cantly inhibited the growth of P12 and C32 tumour out-
growths in xenografted nude mice [175]. To date, MEDI-
573 has been tested in a Phase1 study (NCT00816361) in
subjects with advanced solid tumours. In a currently com-
pleted Phase1b/2 study (NCT01498952), an open-label,
randomized study, MEDI-573 has been tested in combin-
ation with sorafenib, a small molecule inhibitor of several
tyrosine protein kinases (VEGFR and PDGFR) and Raf ki-
nases, in adult subjects with unresectable or metastaticvaluated in clinical trials for the treatment of HCC
l Trial
Status





















Completed Alone and in combination
with sorafenib and erlotinib
HCC not eligible for
local treatment
Completed Alone With advanced HCC after
failure of first-line treatment
with sorafenib
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Since IGFPB3 naturally binds the ligands of the IGF
pathway, non-glycosylated human recombinant IGFBP3
(rhIGFBP3) has been proposed as ligand antagonist. In
in vitro studies, rhIGFBP3 has been reported to signifi-
cantly inhibit cell proliferation of murine lung metastatic
(M-3LL) and human colon metastatic (LoVo) cell lines
[176]. Treatment of HepG2 cells with human rhIGFBP3
led to a significant reduction in cell proliferation and at-
tenuated the mitogenic activity of IGF1 [151].
Anti-receptor approach
IGF1R is considered the main receptor responsible for
the mitogenic effects of the IGF axis [43], therefore, it
represents an attractive target for anti-cancer therapy.
Drugs targeting the IGF1R are also called IGF1R-
blockers and include: anti IGF1R monoclonal antibodies
such as CP-751,871, AVE1642/EM164, IMC-A12, SCH-
717454, BIIB022, AMG 479 and MK-0646/h7C10, and
small molecules RTK inhibitors such as OSI-906 [43].
Several in vitro and in vivo studies have evaluated the ef-
fects of these compounds in different types of preclinical
cancer models, as recently reviewed [43,177]. This re-
view will focus on the studies evaluating the effects of
IGF1R-blockers in HCC.
IMC-A12, also known as cixutumumab, is a fully hu-
man monoclonal IgG1 antibody that binds IGF1R with
high affinity, inhibits ligand-dependent receptor activation
and downstream signalling, and also mediates IGF1R in-
ternalization and degradation [178]. IMC-A12 has shown
antitumoral activity against a wide range of human
tumour types in in vitro studies. The effect of IMC-A12
has been evaluated in human breast (MCF7), pancreas
(BxPC-3), and colon (Colo205) carcinoma cell lines, in
which the antibody inhibits cell proliferation and induces
cell apoptosis [179]. In the same study, IMC-A12 has also
shown activity against a human tumour in both in vivo
xenograft and orthotopic models. Immunohistochemical
studies on tumour biopsies from mice bearing MCF7 tu-
mours, treated with IMC-A12, showed a 20% reduction of
proliferating cells and an increase of apoptotic cells [179].
IMC-A12 treatment induced significant antitumour activ-
ity also in Colo205 and BxPC-3 xenografts, affecting
tumour growth and showing >70% and 80% of growth in-
hibition, in Colo205 and BxPC-3 xenografts, respectively
[179]. IMC-A12 has also shown potent activity, as a single
agent, against xenograft models of human non-small cell
and small cell lung carcinoma, as well as in models of
prostate, renal, thyroid and head and neck carcinoma,
multiple myeloma and sarcoma [180-183]. Nowadays, a
Phase 2 study (NCT00639509) in patients with primary,
advanced, localized unresectable, recurrent HCC, has
been completed. The results of this study showed thatIMC-A12 did not have the expected effects in this cohort
of unselected HCCs. No correlation was found between
IGF1R positive staining and treatment outcome [184].
Phase 1 (NCT01008566) and Phase 2 (NCT00906373) tri-
als with IMC-A12, in combination with sorafenib, are on-
going and the results of these studies are still awaited.
AVE1642 is a humanized version of the murine IGF1R
mAb EM164. In in vitro studies in human HCC cell
lines (HepG2, Hep3B, HuH-7, HuH-6, PLC/PRF5), it has
been demonstrated that AVE1642 inhibits cell prolifera-
tion by preventing the activation of signalling in re-
sponse to exogenous IGF1 and IGF2, but not insulin,
supporting the IGF1R specifity of this antibody [88]. In
the same study, it has been demonstrated that AVE1642
is able to downregulate Akt phosphorylation, and this ef-
fect was increased when AVE1642 was combined with
gefitinib (EGFR inhibitor) or rapamycin (mTOR inhibi-
tor) [88], supporting the efficacy of combined treatments
in HCC. AVE1642 has been tested in a completed Phase
1/2 study (NCT00791544, as single agent and in com-
bination with other anti-cancer therapies, in patients
with advanced HCC not eligible for local treatment; the
results of this study are still awaited.
OSI-906 is a potent and selective small molecule RTK
inhibitor, targeting both IGF1R and IR. This drug com-
pared with the other class of IGF1R blockers has the ad-
vantage to inhibit also the IGF2-induced IRA activation,
which has been reported to favour growth in cancer
[40]. OSI-906 potently inhibits ligand-dependent auto-
phosphorilation of both IGF1R and IR, preventing the
activation of pAkt, pERK1/2, and pp70S6k, and thus inhi-
biting cell proliferation [185]. OSI-906 displays in vitro
antiproliferative effects in several human tumour cell lines
and robust in vivo anti-tumour effects in IGF1R-dependent
mice xenograft model of fibrosarcoma [185]. In an in vitro
study, OSI-906 showed inhibitory effects on cell prolifera-
tion in several HCC cell lines, expecially in those displaying
epithelial phenotype. The inhibitory effect of OSI-906
results in the inhibition of the IRS/Akt pathway [186].
Recently, a randomized, placebo-controlled, double-blind
Phase 2 study (NCT01101906) has been concluded on
patients with advanced HCC after failure of first-line treat-
ment with sorafenib, but the results of this study are still
awaited. Another recent Phase 2 study (NCT01334710)
performed in patients with advanced HCC receiving
OSI-906 in combination with sorafenib has been sus-
pended, for safety reasons, by the pharmaceutical com-
pany. BIIB022, a human anti-IGF1R mAb, has been used
in a Phase 1/b study (NCT00956436) in combination with
sorafenib in patients with advanced HCC, but the results
of this study are still awaited.
IGF1R-blockers have been generally documented to be
well tolerated, but extended blockade of IGF1R signalling
could potentially produce clinical signs and symptoms
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deficiency, including visceral adiposity, dyslipidemia,
deterioration of cardiac performance, osteoporosis, and
impairment of physical and psychological performance
[187,188]. Moreover, several metabolic side effects such
as insulin resistance and gluconeogenesis, could result
secondary to increased GH levels in the absence of
IGF1R function [43].
In conclusion, preclinical studies suggest that agents
targeting IGF axis could provide a promising alternative
treatment in HCC patients. However, the results of clin-
ical trials evaluating the effects of drugs targeting this
axis in HCC patients are awaited.
Somatostatin receptor agonists (SA)
SSTRs are a treatment target in some types of tumours.
Given the short half-life of native SST, several synthetic
SA have been developed and are currently used in clin-
ical practice, mainly to treat patients with neuroendo-
crine tumours (NET) [25]. Among these, the most
important are: octreotide, which binds with high affin-
ity to SSTR2 and with reduced affinity to SSTR3 and
SSTR5; lanreotide, which primarily binds with high af-
finity to SSTR2 but shows reduced or no binding to
SSTR1, 3, 4 and 5 subtypes; pasireotide, which has high
affinity for SSTR5 but it also binds SSTR2, SSTR3
and SSTR1, with decrescent affinity [25,189]. Several
in vitro studies using cell lines transfected with SSTRs
indicate that all receptor subtypes (SSTR1-5) may me-
diate the inhibition of cell proliferation, whereas spe-
cific receptor subtypes (SSTR2, SSTR3) may mediate
the induction of apoptosis [190]. These effects are reg-
ulated primarily via MAPK pathway and through the
activation of phosphotyrosine phosphatases [191,192].
The growth inhibition effects of SA might be also in-
duced by the restoration of functional gap junctions
[192,193]. Moreover, SA could upregulate the tumour
suppressor protein p53 and activate the pro-apoptotic
member of the Bcl-2 protein family, Bax, thus trigger-
ing apoptosis [193].
In a subset of patients with NET, SA have been found
to improve clinical syndrome, to control hormonal
secretion and to inhibit tumour growth [26,194,195].
Additionally, radiolabeled-SA have been developed and
are clinically used to visualize NETs or to perform
radiometabolic treatments in NET patients [25]. SA,
alone or in combination with other antitumour treat-
ments, have been associated with some favourable clinical
outcomes in not classical neuroendocrine solid tumours,
such as prostate cancer, that has been found to express
different SSTR subtypes, including SSTR2 and/or SSTR5
[26]. Therefore, it has been suggested that SSTRs might
be useful also in the clinical management of patients with
other types of tumours expressing SSTRs [25].Many studies have tried to address the role of SA in
HCC treatment but, up to date, both preclinical and
clinical data are still controversial.
The effects of SA in both normal and tumour hepatic
cells have been investigated in several in vitro studies.
The activation of SSTRs results in the inhibition of pro-
liferation in normal liver cell lines and in some, but not
all, neoplastic liver cell lines [27,70,155-157,196]. Par-
ticularly, in the normal liver cell line L-02, octreotide
was found to inhibit cell proliferation and, at the highest
dose, it was found to induce apoptosis [70,189]. The
same study also demonstrated that octreotide was able
to inhibit cell proliferation and to induce apoptosis in
HepG2 and SMMC-7721 HCC cell lines, which ap-
peared to be more sensitive to the proapoptotic effects
of octreotide than normal liver cell line L-02 [70]. How-
ever, these results must be considered carefully, since
the drug concentration used in these in vitro experi-
ments was higher than the maximal dose generally
achieved in the therapeutic regimen of the SA, in the
clinical practice [70]. The effects of octreotide on cell
proliferation have been also tested in human cell lines
with high (MHCC97-H) and low (MHCC97-L) meta-
static potential. These cells were insensitive to the treat-
ment with octreotide, consistently with their lack of
SSTRs expression [197]. None of several subtype specific
SA [L-797,591 (SSTR1 agonist), L-779,976 (SSTR2 agon-
ist), L-796,778 (SSTR3 agonist), L-803,087 (SSTR4 agon-
ist), and L-817,818 (SSTR5 agonist)] affected proliferation
or apoptosis in two human HCC cell lines (HepG2 and
HuH-7), but L-797,591 inhibited the migration of HepG2
and HuH-7 cells in the presence of chemotactic stimuli
[27]. In HepG2 and HepB3 HCC cell lines, AN-238, which
is a cytotoxic agent consisting of 2-pyrrolino-doxorubicin
(AN-201) conjugate to a well-characterized somatostatin
octapeptide carrier, RC-121 (binding SSTR2 and 5)
[198,199], was able to inhibit cell proliferation by indu-
cing cell cycle block in sub-G1 phase and to induce
apoptosis by triggering DNA fragmentation and cleav-
age of poly ADP-ribose polymerase (PARP) protein
[157]. The role of the new universal SA pasireotide on
HCC cell proliferation has also been recently investi-
gated. In HepG2 cell line, treatment with pasireotide,
alone or combined with celecoxib, inhibited cell viability
in a dose dependent manner [200].
SA showed some antitumoral effects also in in vivo
preclinical models of HCC. Treatment with octreotide
inhibited tumour growth in nude mice bearing HCC xe-
nografts [148]. Additionally, octreotide and pasireotide
induced tumour necrosis, probably inhibiting VEGF ex-
pression [197,201,202]. The anti-vascular effects of SA
have been supported also by in vitro and in vivo studies
in experimental models of angiogenesis [203-205]. In an
animal model of hepatocarcinogenesis, the effects of
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this study rats were treated chronically with a carcino-
genic drug and they were assigned to three treatment
groups: rats receiving lanreotide from the beginning of
the experiment, rats receiving lanreotide at the onset of
fibrosis, and rats not receiving lanreotide (control group).
In both the groups receiving lanreotide the frequency of
HCC was decreased of about 60%, compared with control
group. Decrease in hepatocytes proliferation and inhib-
ition of fibrosis were also demonstrated. Additionally,
when given at the start of the experiment, lanreotide
dramatically decreased the levels of angiogenic factors
and enhanced apoptosis [206].
Several case reports and clinical trials regarding the
use of SA in the management of patients with HCC have
been reported. In one of the first case reports on ad-
vanced HCC, lanreotide slow-release (lanreotide SR) was
administered in order to manage para-neoplastic diar-
rhea. After two intramuscular injections of lanreotide SR
at a dose of 30 mg every 10 days, the alpha-fetoprotein
(AFP), an important tumour marker for HCC, levels
were drastically reduced and when lanreotide therapy
was continued, given the good tolerance to the treat-
ment, a slight decrease of tumour size with pronounced
signs of necrotic changes were also registered [207]. The
long-acting release formulation of octreotide (octreotide
LAR), at a dose of 10 mg administered monthly, has
been proven to be useful in the treatment of HCC,
resulting in AFP levels normalization and a complete
and prolonged regression of the tumour in a patient with
not resectable HCC [208]. The clinical use of octreotide
LAR has been shown to be useful in a patient with meta-
static HCC, in which it improved quality of life (QoL)
and reduced AFP levels and tumour size [209]. Recently,
lanreotide SR at the dose of 30 mg, administered twice a
month, has been used to treat a patient with recurrent
HCC and lung and mediastinal nodes metastases, after
primary tumour complete resection. In this patient,
the expression of SSTR2 was demonstrated on both
primary tumour and metastases, and three months of
treatment with lanreotide SR 30 mg administered twice
a month induced a decrease in the size of the medias-
tinal nodes and complete disappearance of the lung
nodes [210]. Schematic descriptions of case reports are
presented in Table 2.
Despite these positive case reports, to date several ran-
domized and non-randomized clinical trials conducted
in unresectable HCC patients using octreotide or lanreo-
tide reported conflicting results. Several prospective
non-randomized trials investigated the role of octreotide
LAR or lanreotide, as summarized in Table 3. Dimitrou-
lopoulos et al. enrolled 28 cirrhotic patients with ad-
vanced HCC. Octreoscan for the detection of SSTRs was
performed in all cases. In patients showing intenseuptake in the liver, octreotide was administered as fol-
lows: all patients started treatment with octreotide
0.5 mg, administered subcoutaneously every 8 hrs for
6 weeks. After 4 weeks, treatment with ocreotide LAR
20 mg/4 weeks was added, and between week 4 and
week 6 both treatments were administered. From week
8, patients received only octreotide LAR 20 mg every
4 weeks, uptitrated to 30 mg every 4 weeks from week
12. Thirteen patients unable to receive treatment were
used as control group. Neither AFP reduction nor de-
crease of tumour mass were observed, but treatment im-
proved both median survival time and QoL [211]. Gill et al.
compared the outcomes of 22 patients with inoperable
HCC treated with octreotide and 20 HCC patients that
refused treatment due to socio-economic issues (control
group). Patients received octreotide 100 μg subcutane-
ously, twice a day for 2 weeks. This treatment was
followed by a monthly intramuscular administration of
20 mg octreotide LAR. In this study octreotide LAR
treatment induced tumour size regression, AFP level de-
crease and QoL improvement [212]. In the non-
randomized study of Samonakis et al. the survival of 32
patients with inoperable HCC treated with long acting
SA (octreotide LAR or lanreotide SR) has been com-
pared with a historical control group of 27 untreated pa-
tients. In these patients, the use of long acting SA
appeared to have a positive effect on survival and QoL
in inoperable HCC cases [213]. Plentz et al. recruited 41
patients with advanced HCC and cirrhosis, including
predominantly alcoholic, and HBV and HCV-induced
secondarily cirrhosis, treated with short-acting and
long-acting octreotide. Patients started the treatment
with 50 mg of subcutaneously administrated short-
acting octreotide, 3 times a day in the first week. The
octreotide dose was increased by 50 mg per application
each week until a final dose of 250 mg octreotide, 3
times a day, was reached. After this regimen, patients
received 30 mg intramuscular octreotide LAR, once
every 4 weeks. These patients were compared with a
group of patients treated with transarterial chemoembo-
lization (TACE) and no difference in median survival
was registered [214]. Schoniger-Hekele et al. studied
retrospectively the influence of octreotide LAR mono-
therapy on survival of patients with HCC and compared
it to BCLC stage-matched patients who received either
TACE, multimodal therapy, or palliative care only. Their
study demonstrated that in the subgroup of 55 patients,
classified as BCLC stage B, survival rates of patients with
"active" treatments (octreotide LAR, TACE or multimodal
therapy) were significantly higher than those of patients
who received only palliative care. In both BCLC stage A
and B patients, octreotide monotherapy showed a similar
outcome, compared with patients who received TACE or
multimodal therapy [215]. Slijkhuiset al. investigated the
Table 2 Case reports of HCC treatment with SA monotherapy
Publication Type of study Number of
enrolled patients
and controls
Type of Cancer SA used for treatment Response to
treatment-outcome
Patients Controls
Raderer 1999 [207] Case report 1 - Advanced HCC LAN SR
(30 mg/10d)
↓AFP, ↑TN, SD
Siveke 2003 [208] Case report 1 - Advanced HCC OCT LAR
(10 mg/28d)
CR, ↓AFP
Deming 2005 [209] Case report 1 - Metastatic HCC OCT LAR
(30 mg)
↑QoL, ↓AFP, PR
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http://www.infectagentscancer.com/content/9/1/27effect of octreotide LAR in a prospective uncontrolled
study. Initially, 30 patients received short-acting octreotide
to ensure drug tolerability. Thereafter, 24 patients received
octreotide LAR 30 mg every 4 to 6 weeks. In this study,
median time to tumour progression was 3.6 months, and
median survival was 5.1 months; 7 patients (29%) had
stable disease (median duration of 8.0 months) with 2 pa-
tients demonstrating disease stability for 24 months [216].
In a study of our research group, 20 patients with advanced
HCC were treated with octreotide LAR 30 mg/month and
a pool of 40 patients with HCC with tumour staging and
liver function comparable to the study patients wasTable 3 Non randomized clinical trials of HCC treatment with
Publication Type of study Number of enrolled
patients and controls
Patients Controls
Dimitroulopoulos 2002 [211] NRCT 15* 13#
Gill 2005 [212] NRCT 22* 20#
Samonakis 2002 [213] NRCT 32* 27#
Plentz 2005 [214] NRCT 41* 33▪
Schoniger-Hekele 2009 [215] NRCT 25* 39†
or 17▪
or 17▫
Slijkhuis 2005 [216] NRCT 30* -












†: palliative.retrospectively selected as control. The patients treated
with octreotide LAR showed a significantly higher mean
survival rate, compared with controls, and patients’ sur-
vival was significantly correlated with SSTR2 messenger
expression in the tumour [217]. In a phase 2 multicenter
study (So.LAR.), 55 patients with advanced HCC, Child-
Pugh A or B, received sorafenib at a dosage of 800 mg/day
for 28 days with a following week of rest and octreotide
LAR at a dose of 40 mg, administered every 28 days.
Treatment was well tollerated and partial response was
documented in 10%, whereas a stable disease was
achieved in 66% of patients after treatment. This studySA monotherapy
Type of Cancer SA used for treatment Response to
treatment-outcome
Advanced HCC OCT LAR (20 to 30 mg/28d) ↑S, ↑QoL
Advanced HCC OCT LAR (20 mg/28d) ↑S, ↑QoL, ↓AFP, PR
Advanced HCC NS ↑S, ↑QoL,
Advanced HCC OCT LAR (30 mg/28d) =S
Advanced HCC OCT LAR (30 mg/28d) ↑S
Advanced HCC OCT LAR (30 mg/28d) SD
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http://www.infectagentscancer.com/content/9/1/27demonstrated that this combination of treatments can
be a safe and effective option [218]. In a following
study the authors investigated, in patients included in
the So.LAR study, whether oxidative stress evaluated in
biological samples, including both serum and peripheral
blood mononuclear cells (PBMC), and pERK activation sta-
tus in PBMC, could be predictive of response. The results
of this study suggested that the levels of nitric oxide activity
were correlated with the prognosis of HCC patients treated
with So.LAR schedule and that the determination of
both pERK expression in PBMC and the oxidative stress
status could have a value in the prediction of response to
sorafenib plus octreotide therapy in HCC patients [219].
To our knowledge, five randomized clinical trials have
been performed to investigate the role of octreotide in
the management of unresectable HCC, as presented in
Table 4. Kouroumalis et al. enrolled 58 patients and ran-
domly assigned them to two groups: 28 patients received
octreotide 250 μg twice a day, whereas 30 patients did
not receive any treatment and were considered as con-
trol group. Octreotide administration significantly im-
proved median survival and cumulative survival rate at 6
and 12 months, as compared with control group, by de-
creasing AFP levels and by improving QoL after
6 months of treatment [220]. Yuen et al. performed a
study with 70 patients, randomized in octreotide LAR
treated group and placebo group and did not find a sig-
nificant improvement in survival rate, AFP levels or QoL
[221]. The value of scintigraphic uptake for predicting
the therapeutic response to SA has been proven for NET
[222]. Dimitroulopoulos et al. recruited 127 patients: 61
positive and 66 negative to Octreoscan. Patients positive
to Octreoscan were randomized in two groups: 31
patients were treated with octreotide administeredTable 4 Randomized clinical trials of HCC treatment with SA m
Publication Type of study Number of enrolle
patients and contro
Patients Control
Kourumalis 1998 [220] RCT 28* 30#
Yuen 2002 [221] RCT 35* 35°
Dimitroulopoulos 2007 [166] RCT 24* (Octreoscan +) 30° (Oct
66# (Oct
Becker 2007 [223] RCT 60* 59°
Barbare 2009 [224] RCT 135* 137°
RCT, Randomized clinical trial.
AFP, Alpha fetoprotein.
S, Survival.
QoL, Quality of life.
*: treated patients.
#: untreated patients.
°: placebo controls.subcutaneously at the dose of 0.5 mg every 8 hrs for
6 weeks and then octreotide LAR at the dose of 20 mg
at the end of week 4–8; the remaining 30 patients re-
ceived placebo. A significantly higher survival time and
QoL were observed in the octreotide treated group, as
compared with the control group and to the SSTRs
negative group [166]. Becker et al. conducted a random-
ized, controlled trial, analyzing 119 patients, divided in 60
patients treated with octreotide LAR at the dose of 30 mg
monthly, and 59 patients treated with placebo. They ob-
served no survival improvement and no AFP reduction in
HCC patients treated with octreotide LAR, compared
with patients treated with placebo [223]. Barbere et al. en-
rolled 272 patients randomly assigned to octreotide LAR
treated group (135) and to placebo group (137). The re-
sults of this study established that octreotide does not pro-
long patients’ survival and has a negative impact on QoL
[224]. In summary, among the randomized trials, only the
two Greek studies reported benefits from octreotide treat-
ment, whereas the German, French and Chinese trials did
not show any advantage from the therapy with octreotide.
Because of the contradictory results of all these studies,
the use of SA in the management of HCC is still matter of
debate. These confliting results could depend on the het-
erogeneous methodology used and heterogeneous popula-
tion enrolled in the study. Indeed, both the positive
studies had a high proportion of HCV related HCC and a
low proportion of alcoholic related HCC. Additionally,
only one of the positive studies explored the effects of
octreotide in a cohort of patients selected on the basis of
octreoscan positivity [166]. Overall, the results of these
studies demostrated that approximately 40% of HCC pa-
tients responded to SA treatment with an improvement
of survival rate and an improvement of QoL, but someonotherapy
d
ls





Advanced HCC OCT SC
(500 μg/d)
↓AFP,↑S, ↑QoL
Advanced HCC OCT LAR
(30 mg/28d)
None
reoscan +) Advanced HCC OCT LAR
(20 to 30 mg/28d)
↑S, ↑QoL
reoscan -)
Advanced HCC OCT LAR
(30 mg/28d)
None
Advanced HCC OCT LAR
(30 mg/28d)
=S, ↓QoL
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http://www.infectagentscancer.com/content/9/1/27subsets of patients, such as the Octreoscan-positive or
those with HCV-related HCC, might be better candi-
dates for this treatment. However, further studies are
mandatory to better address the role of SA in the man-
agement of patients with HCC and to better explore the
role of aetiology, SSTR expression, or Octreoscan posi-
tivity, as predictors of response to this treatment. Lastly,
to our knowledge, no data are available regarding the
use of pasireotide in patients with HCC.
In conclusion, both preclinical and clinical data sug-
gest that SA might have antitumoural effects in a subset
of HCC, further studies are required to better define the
role of SA in the management of HCC patients.
Conclusions
GH-IGF-SST system seems to play a role in the develop-
ment and progression of HCC, although the real impact of
this system, either in physiologic or pathologic conditions,
on hepatocarcinogenesis is still far from being completely
understood. GH-IGF-SST system might potentially repre-
sent a target for treatment of HCC. However, drugs target-
ing IGF pathway and SSTRs seem to be less promising
than expected, although clinical trials in selected cohorts of
patients or with combined treatment could give better re-
sults. Therefore, an open challenge in this field is to define
whether GH-IGF-SST system is a good target for treatment
in specific subgroups of HCC patients, whether there are
predictive biomarkers that can help to early identify the pa-
tients potentially responsive to this treatment, and whether
combined therapy with multiple drugs targeting this path-
way can be more effective than drugs used as monotherapy.
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